Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27448156 | 0.88 | KDM4E (0.41) | KDM4EGPBAR1ALDH1A1PDE4A | |
| SCHEMBL27443608 | 0.88 | KDM4E (0.41) | KDM4EGPBAR1ALDH1A1PDE4A | |
| SCHEMBL20224631 | 0.88 | KDM4E (0.38) | KDM4EGPBAR1ALDH1A1PDE4A | |
| SCHEMBL23813853 | 0.87 | GPBAR1 (0.35) | KDM4EGPBAR1ALDH1A1 | |
| SCHEMBL18494029 | 0.81 | MMP8 (0.41) | ALDH1A1 | |
| SCHEMBL23813884 | 0.80 | KDM4E (0.38) | KDM4EPDE4A | |
| SCHEMBL22738631 | 0.79 | KDM4E (0.46) | KDM4EGPBAR1ALDH1A1PDE4A | |
| SCHEMBL20224696 | 0.79 | GPBAR1 (0.35) | KDM4EGPBAR1ALDH1A1 | |
| SCHEMBL27315841 | 0.79 | KDM4E (0.43) | KDM4EGPBAR1ALDH1A1PDE4A | |
| SCHEMBL25950269 | 0.79 | KDM4E (0.43) | KDM4EGPBAR1ALDH1A1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029736-B2 | Camptothecin derivatives and conjugates thereof | MEDIBOSTON LIMITED (HK) | 2024-07-09 | — | — | US | disclosed |
| US-12029736-B2 | Camptothecin derivatives and conjugates thereof | MEDIBOSTON LIMITED (HK) | 2024-07-09 | — | — | US | disclosed |
| US-20210283125-A1 | CAMPTOTHECIN DERIVATIVES AND CONJUGATES THEREOF | FORTVITA BIOLOGICS LIMITED (CN) | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283125-A1 | CAMPTOTHECIN DERIVATIVES AND CONJUGATES THEREOF | TOP2A, TOP1, XPA | KDM4E 3831/4885GPBAR1 3749/4885ALDH1A1 1163/4885 |
| US-12029736-B2 | Camptothecin derivatives and conjugates thereof | TOP2A, TOP1, XPA | KDM4E 3831/4885GPBAR1 3749/4885ALDH1A1 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.